Clinical Trial Update: Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update discusses response-based dose reduction of Linvoseltamab in relapsed/refractory multiple myeloma across Phase 1 and Phase 2. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Linvoseltamab

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING